Prieto Luis, Romero Jesús, López Cristóbal, Ortiz Manuel, Pacheco Juan Jose
Urodynamics Unit, Department of Urology, San Juan University Hospital, San Juan/Alicante, Spain.
Urol Int. 2008;81(1):66-71. doi: 10.1159/000137643. Epub 2008 Jul 16.
To evaluate the efficacy of modified-release doxazosin 4 mg in the treatment of patients with acute urinary retention (AUR) due to benign prostate gland hyperplasia (BPH). An evaluation is made of the number of patients recovering spontaneous micturition after catheter removal, micturition quality, and the number of patients suffering new AUR episodes or who require surgery in the 2 years following the first episode.
A randomized, controlled study in males with AUR secondary to BPH. Two groups are formed, administering modified-release doxazosin 4 mg to patients born in even-numbered years, once a day in the morning. Those born in odd-numbered years receive no medication. The catheter is withdrawn 1 month later. Flowmetry is performed, with determination of ultrasonographic postmicturition retention at withdrawal, and after 6, 12 and 24 months.
Of the 65 patients included, 47 proved evaluable, and 46 complied with treatment (with exclusion of 1 case due to hypotension). Of the 22 patients treated with doxazosin, 15 (68.86%) presented AUR after 2 years, while 7 (31.2%) showed spontaneous micturition. Of the 24 patients treated with bladder catheterization in the absence of medication, 16 (66.6%) presented AUR after the same period of time, while 8 (33.3%) showed spontaneous micturition. There were no statistically significant differences between the treated and untreated subjects in terms of drug efficacy. Residual flow parameters are described in the population with spontaneous micturition in each stage of the study.
In our series, treatment with the alpha-blocker doxazosin (4 mg, modified-release formulation), added to bladder catheterization, showed no increased efficacy in AUR treatment versus catheterization alone. Two years after the urinary retention episode, 31.2% of the patients treated with modified-release doxazosin 4 mg, and 33.3% of those with a bladder catheter only were seen to maintain spontaneous micturition.
评估4毫克缓释多沙唑嗪治疗良性前列腺增生(BPH)所致急性尿潴留(AUR)患者的疗效。对拔除导尿管后恢复自主排尿的患者数量、排尿质量以及在首次发作后2年内出现新的急性尿潴留发作或需要手术的患者数量进行评估。
对继发于BPH的AUR男性患者进行一项随机对照研究。分为两组,偶数年份出生的患者服用4毫克缓释多沙唑嗪,每天早晨一次。奇数年份出生的患者不接受药物治疗。1个月后拔除导尿管。进行尿流率测定,在拔除导尿管时、6个月、12个月和24个月后测定超声排尿后残余尿量。
纳入的65例患者中,47例可评估,46例完成治疗(排除1例因低血压导致的病例)。在接受多沙唑嗪治疗的22例患者中,15例(68.86%)在2年后出现急性尿潴留,而7例(31.2%)表现为自主排尿。在未用药仅接受膀胱导尿治疗的24例患者中,16例(66.6%)在同一时期出现急性尿潴留,而8例(33.3%)表现为自主排尿。治疗组和未治疗组在药物疗效方面无统计学显著差异。在研究的每个阶段,对自主排尿人群的残余尿流参数进行了描述。
在我们的研究系列中,在膀胱导尿基础上加用α受体阻滞剂多沙唑嗪(4毫克,缓释制剂)治疗急性尿潴留,与单纯导尿相比,疗效并未提高。尿潴留发作2年后,服用4毫克缓释多沙唑嗪治疗的患者中有31.2%,仅接受膀胱导尿的患者中有33.3%维持了自主排尿。